glp 1 where is it produced GLP-1: Actions on Beta-cell Mass and Function Glucagon-like peptide-1: Trends in Endocrinology

The condition is rare, with an annual incidence rate estimated between 2.3 to 10.2 per 100,000 people over 50 years of age in the U.S

Limitations of Clinical Trials (relevant for setting expectations): Highly selected participants (extensive exclusion criteria) Regular monitoring and support (monthly visits) Free medication (eliminates cost/access barriers) Intensive lifestyle interventions (may exceed real-world adherence) Short duration (68-72 weeks) relative to chronic disease treatment needs Real-World Studies Findings : According to real-world evidence published in peer-reviewed journals examining semaglutide and tirzepatide use in routine clinical practice: Weight loss magnitude is generally lower than clinical trial averages Discontinuation rates are often higher due to side effects, cost, or access issues Adherence rates vary widely (50-80% at 12 months in various studies) Weight regain after discontinuation is common Cardiovascular and metabolic benefits are observed even with modest weight loss Clinical Data Interpretation: Clinical trial results represent average outcomes under ideal conditions

Is tirzepatide better than Ozempic for cortisol-driven weight problems

Since starting her weight loss journey, she has become a health coach, drawing from her personal experience to inspire others

Cortisol drops to its lowest levels

Ozempic, FDA-approved for diabetes), tirzepatide (Zepbound, FDA-approved for weight management